Literature DB >> 20652276

Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease.

Katherine J E Sattler1, Sehriban Elbasan, Petra Keul, Miriam Elter-Schulz, Constantin Bode, Markus H Gräler, Martina Bröcker-Preuss, Thomas Budde, Raimund Erbel, Gerd Heusch, Bodo Levkau.   

Abstract

High-density lipoproteins (HDL) are the major plasma carriers for sphingosine 1-phosphate (S1P) in healthy individuals, but their S1P content is unknown for patients with coronary artery disease (CAD). The aim of the study was to determine whether the S1P levels in plasma and HDL are altered in coronary artery disease. S1P was determined in plasma and HDL isolated by ultracentrifugation from patients with myocardial infarction (MI, n = 83), stable CAD (sCAD, n = 95), and controls (n = 85). In our study, total plasma S1P levels were lower in sCAD than in controls (305 vs. 350 pmol/mL). However, normalization to HDL-cholesterol (a known determinant of plasma S1P) revealed higher normalized plasma S1P levels in sCAD than in controls (725 vs. 542 pmol/mg) and even higher ones in MI (902 pmol/mg). The S1P amount contained in isolated HDL from these individuals was lower in sCAD than in controls (S1P per protein in HDL: 132 vs. 153 pmol/mg). The amount of total plasma S1P bound to HDL was lower in sCAD and MI than in controls (sCAD: 204, MI: 222, controls: 335 pmol/mL), while the non-HDL-bound S1P was, accordingly, higher (sCAD: 84, MI: 81, controls: 10 pmol/mL). HDL-bound plasma S1P was dependent on the plasma HDL-C in all groups, but normalization to HDL-C still yielded lower HDL-bound plasma S1P in patients with sCAD than in controls (465 vs. 523 pmol/mg). The ratio of non-HDL-bound plasma S1P to HDL-C-normalized HDL-bound S1P was also higher in both sCAD (0.18 mg/mL) and MI (0.15 mg/mL) than in controls (0.02 mg/mL). Remarkably, levels of non-HDL-bound plasma S1P correlated with the severity of CAD symptoms as graded by Canadian Cardiovascular Score, and discriminated patients with MI and sCAD from controls. Furthermore, a negative association was present between non-HDL-bound plasma S1P and the S1P content of isolated HDL in controls, but was absent in sCAD and MI. Finally, MI patients with symptom duration of less than 12 h had the highest levels of total and normalized plasma S1P, as well as the highest levels of S1P in isolated HDL. The HDL-C-normalized plasma level of S1P is increased in sCAD and even further in MI. This may be caused by an uptake defect of HDL for plasma S1P in CAD, and may represent a novel marker of HDL dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652276     DOI: 10.1007/s00395-010-0112-5

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  68 in total

1.  Plasma apoM and S1P levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus.

Authors:  Mingxia Liu; Cecilia Frej; Carl D Langefeld; Jasmin Divers; Donald W Bowden; J Jeffrey Carr; Abraham K Gebre; Jianzhao Xu; Benny Larsson; Björn Dahlbäck; Barry I Freedman; John S Parks
Journal:  J Lipid Res       Date:  2019-05-27       Impact factor: 5.922

2.  High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease.

Authors:  Anandita P Agarwala; Amrith Rodrigues; Marjorie Risman; Mary McCoy; Kevin Trindade; Liming Qu; Marina Cuchel; Jeffrey Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

3.  A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection.

Authors:  Ludovic Gomez; Melanie Paillard; Megan Price; Qun Chen; Geoffrey Teixeira; Sarah Spiegel; Edward J Lesnefsky
Journal:  Basic Res Cardiol       Date:  2011-10-15       Impact factor: 17.165

4.  Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA activation and cardioprotection.

Authors:  Bryan S Yung; Cameron S Brand; Sunny Y Xiang; Charles B B Gray; Christopher K Means; Hugh Rosen; Jerold Chun; Nicole H Purcell; Joan Heller Brown; Shigeki Miyamoto
Journal:  J Mol Cell Cardiol       Date:  2016-12-23       Impact factor: 5.000

5.  Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques.

Authors:  Hui Liu; Hongjun Jin; Junbin Han; Xuyi Yue; Hao Yang; Mohamed A Zayed; Robert J Gropler; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 6.  Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress.

Authors:  Joel S Karliner
Journal:  Biochim Biophys Acta       Date:  2012-06-23

Review 7.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

Review 8.  Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells.

Authors:  Xing Liu; Qing-Hai Zhang; Guang-Hui Yi
Journal:  Mol Cell Biochem       Date:  2011-11-24       Impact factor: 3.396

Review 9.  Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis.

Authors:  Linda Sasset; Yi Zhang; Teresa M Dunn; Annarita Di Lorenzo
Journal:  Trends Endocrinol Metab       Date:  2016-08-22       Impact factor: 12.015

Review 10.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.